[HTML][HTML] Targeting autophagy for cancer treatment and tumor chemosensitization

M Pérez-Hernández, A Arias, D Martínez-García… - Cancers, 2019 - mdpi.com
… of tumors, and has already demonstrated positive clinical results in patients. In this review, …
modulation has shown controversial results in preclinical studies. For instance, it has been …

Combination therapy of chemotherapy or radiotherapy and the neurokinin-1 receptor antagonist aprepitant: A new antitumor strategy?

P Robinson, R Coveñas… - Current Medicinal …, 2023 - ingentaconnect.com
… the antitumor activity (chemosensitization) of cisplatin in … In addition to the in vitro preclinical
studies, further studies to … done using patient-derived xenografts (PDX’s) in preclinical animal …

Preclinical pharmacokinetics of benznidazole

P Workman, RA White, MI Walton, LN Owen… - British journal of …, 1984 - nature.com
… lipophilicity was particularly important for chemosensitization. The lipophilic analogue
benznidazole (N… These doses are similar to those used in our previous chemosensitization studies

Regulatory considerations for preclinical development of anticancer drugs

JJ DeGeorge, CH Ahn, PA Andrews, ME Brower… - Cancer chemotherapy …, 1997 - Springer
… Thus, it is important to know the plasma elimination half-life (and, if possible, tissue
elimination half-lives) in preclinical studies so that the length of time a patient should protect …

Nitric oxide and platinum-derivative-based regimens for cancer treatment: from preclinical studies to clinical trials

S Plenchette, C Paul, A Bettaieb - … (Donor/Induced) in Chemosensitizing, 2017 - Elsevier
patients with a wide variety of solid tumors. New effective strategies are still needed to improve
chemosensitizationPreclinical and clinical studies focused on combination therapy using …

[HTML][HTML] Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents

Y Shaked, E Henke, JML Roodhart, P Mancuso… - Cancer cell, 2008 - cell.com
… A third hypothesis, which essentially provides a mechanistic explanation for the second
hypothesis, is based on our prior preclinical observations regarding the induction of circulating …

Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors

SH Song, B Yu, Y Wei, MG Wientjes, JLS Au - Clinical cancer research, 2004 - AACR
… less conventional in preclinical studies, they are used routinely in clinical drug evaluation. On
… -dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. …

In vivo evidence of γ-tocotrienol as a chemosensitizer in the treatment of hormone-refractory prostate cancer

WN Yap, N Zaiden, SY Luk, DTW Lee, MT Ling… - Pharmacology, 2010 - karger.com
… reducing the toxicity often seen in patients treated with DTX. … promising treatment strategy
for patients with AIPCa. Finally, we … development of future preclinical and clinical studies on the …

Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides

H Miayake, A Tolcher, ME Gleave - Journal of the National …, 2000 - academic.oup.com
… have been traditionally evaluated in patients with advanced … preclinical data provide
support for clinical studies with antisense Bcl-2 oligodeoxynucleotides plus paclitaxel for patients

Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs

A Goel, BB Aggarwal - Nutrition and cancer, 2010 - Taylor & Francis
… These preclinical studies are expected to lead to clinical trials to prove the potential of this
age-old golden spice for treating cancer patients. … This review summarizes the potential role of …